Your browser doesn't support javascript.
loading
PCSK9 inhibitor recaticimab for hypercholesterolemia on stable statin dose: a randomized, double-blind, placebo-controlled phase 1b/2 study.
Xu, Mingtong; Zhu, Xiaoxue; Wu, Junyan; Zhang, Yuling; Zhao, Dong; Wang, Xuhong; Ding, Yanhua; Cao, Yu; Li, Chengqian; Hu, Wei; Sheng, Jianlong; Luo, Zhu; Zheng, Zeqi; Hu, Jinfang; Liu, Jianying; Zhou, Xiaoyang; Shen, Aizong; Ding, Xiaomei; Zhang, Yongdong; Zhao, Yonggang; Li, Yijing; Zhong, Sheng; An, Shimin; Zou, Jianjun; Yan, Li.
Afiliación
  • Xu M; Department of Endocrinology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, No. 107 Yanjiang Road West, Guangzhou, 510120, China.
  • Zhu X; Phase I Clinical Trials Unit, The First Hospital of Jilin University, Changchun, China.
  • Wu J; Department of Pharmacy, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
  • Zhang Y; Department of Cardiology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
  • Zhao D; Endocrinology Center, Capital Medical University, Beijing Luhe Hospital, Beijing, China.
  • Wang X; Endocrinology Center, Capital Medical University, Beijing Luhe Hospital, Beijing, China.
  • Ding Y; Phase I Clinical Trials Unit, The First Hospital of Jilin University, Changchun, China.
  • Cao Y; Phase I Clinical Research Center, The Affiliated Hospital of Qingdao University, Qingdao, China.
  • Li C; Department of Endocrinology, The Affiliated Hospital of Qingdao University, Qingdao, China.
  • Hu W; Department of Pharmacology, The Second Hospital of Anhui Medical University, Hefei, China.
  • Sheng J; Department of Cardiology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.
  • Luo Z; Department of Clinical Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, China.
  • Zheng Z; Department of Cardiology, The First Affiliated Hospital of Nanchang University, Nanchang, China.
  • Hu J; Department of Pharmacy, The First Affiliated Hospital of Nanchang University, Nanchang, China.
  • Liu J; Department of Endocrinology and Metabolism, The First Affiliated Hospital of Nanchang University, Nanchang, China.
  • Zhou X; Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China.
  • Shen A; Department of Pharmacy, Anhui Provincial Hospital Affiliated to Anhui Medical University, Hefei, China.
  • Ding X; Department of Cardiology, Anhui Provincial Hospital Affiliated to Anhui Medical University, Hefei, China.
  • Zhang Y; Department of Pharmacy, Chenzhou First People's Hospital, Chenzhou, China.
  • Zhao Y; Department of Emergency Medicine, Chenzhou First People's Hospital, Chenzhou, China.
  • Li Y; Clinical Research & Development, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China.
  • Zhong S; Clinical Research & Development, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China.
  • An S; Clinical Research & Development, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China.
  • Zou J; Clinical Research & Development, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China.
  • Yan L; Department of Endocrinology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, No. 107 Yanjiang Road West, Guangzhou, 510120, China. yanli@mail.sysu.edu.cn.
BMC Med ; 20(1): 13, 2022 01 18.
Article en En | MEDLINE | ID: mdl-35039035
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Inhibidores de PCSK9 / Hipercolesterolemia Tipo de estudio: Clinical_trials Idioma: En Revista: BMC Med Asunto de la revista: MEDICINA Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Inhibidores de PCSK9 / Hipercolesterolemia Tipo de estudio: Clinical_trials Idioma: En Revista: BMC Med Asunto de la revista: MEDICINA Año: 2022 Tipo del documento: Article